Table II.
Quantitative Assessment of prognostic factors.
| Prognostic factor | Type | Quantitative change in prognosis (OS) |
|---|---|---|
| 20 gene set | ADC | 6 (66) |
| CDX2 (positive) | ADC | 3,5 (38) |
| CX3CL1 (low) | ADC (smokers) | 3 (23) |
| Signaling proteins: c-SRC, cyclin E1, TTF1, p65, CHK1, and JNK1 | ADC | 2,75 (5) |
| 4 gene set | ADC | 2,5 (66) |
| LINC00152 (low) | ADC | 2,5 (62) |
| CK20 (positive) | ADC | 2,5 (38) |
| CEA (negative) | ADC | 2 (38) |
| PINK1 | ADC | 2 (25)(26)(27) |
| Ki-67 (low) | ADC | 2 (24) |
| MIR31HG, CDKN2A-AS1, LINC01600 (as set) | ADC | 1.5 (65) |
| IL-33 (high) | ADC | 1,5 (34) |
| EGFL6 (low) | ADC | 1,5 (30) |
| Flotillin 1 (low) | LC | 2 (35) |
| Flotillin 2 (low) | LC | 1.75 (35) |
| TMB (high) | NSCLC | 12.25 (69) |
| miRNA-340 (high) | NSCLC | 4 (54) |
| TIMP1/miRNA-125a-5p (low) | NSCLC | 3.25 (55) |
| FOXM1 (negative) | NSCLC | 3 (31) |
| MiRNA 494-3p (low) | NSCLC | 2.75 (57) |
| Girdin (low) | NSCLC | 2.75 (14) |
| STAT3 (low) | NSCLC | 2.5 (14) |
| Girdin and STAT3 (low) | NSCLC | 2.5 (14) |
| Cav3.1 (low) | NSCLC | 2.25 (41) |
| HSF1 (low) | NSCLC | 2.25 (15) |
| CD57 (high) | NSCLC | 2 (44) |
| HURP (low) | NSCLC | 1.75 (43) |
| EMAF (low) | NSCLC | 1.5 (67) |
| miRNA 148a (high) | NSCLC | 1.5 (58) |
| ARHGEF39 (negative) | NSCLC | 1.25 (42) |
| Signaling proteins: EGFR, p38α, AKT1, SOX2, and E-cadherin | SCC | 10 (5) |
| miRNA-590 (high) | SCC | 2.25 (49) |
| IGF2BP2-AS1 and DGCR5 (as set) | SCC | 1.5 (65) |
The quantitative change in prognosis is to some extent a subjective value. In cases where authors of the original study calculated the HR, The prediction value is HR rounded to the nearest quarter. When it was not calculated in a previous study, it is mean survival of two groups compared, or a value based on a Kaplan-Meier curve analysis. miRNA, microRNA; OS, overall survival; ADC, adenocarcinoma; SCC, squamous cell carcinoma; NSCLC, non-small cell carcinoma; LC, lung carcinoma.